Evidence map›Paper›PMID 31258993›Full record

ArticleAMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science2019

Using Similarity Metrics on Real World Data and Patient Treatment Pathways to Recommend the Next Treatment.

Kyle Haas, Stuart Morton, Simone Gupta, Malika Mahoui

Open access · greenAbstract read
In one paragraph

Article in AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Kyle HaasIndiana University-Purdue University Indianapolis (IUPUI), Indianapolis, IN, USA.
Stuart MortonEli Lilly and Company, Indianapolis, IN, USA.
Simone GuptaEli Lilly and Company, Indianapolis, IN, USA.
Malika MahouiEli Lilly and Company, Indianapolis, IN, USA.
Eli Lilly (United States) · USIndiana University – Purdue University Indianapolis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small-cell lung cancer (NSCLC) is one of the most prevalent types of lung cancer and continues to have an ominous five year survival rate. Considerable work has been accomplished in analyzing the viability of the treatments offered to NSCLC patients; however, while many of these treatments have performed better over populations of diagnosed NSCLC patients, a specific treatment may not be the most effective therapy for a given patient. Coupling both patient similarity metrics using the Gower similarity metric and prior treatment knowledge, we were able to demonstrate how patient analytics can complement clinical efforts in recommending the next best treatment. Our retrospective and exploratory results indicate that a majority of patients are not recommended the best surviving therapy once they require a new therapy. This investigation lays the groundwork for treatment recommendation using analytics, but more investigation is required to analyze patient outcomes beyond survival.

Identifiers

PMID31258993
PMCPMC6568112
OpenAlexW2981757691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.